Collegium Pharmaceutical Stock In The News
| COLL Stock | USD 29.96 0.19 0.63% |
Our overall analysis of Collegium Pharmaceutical's news coverage and content from conventional and social sources shows investors' bearish mood towards Collegium Pharmaceutical. The specific impact of Collegium Pharmaceutical news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Collegium Pharmaceutical's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Collegium Pharmaceutical headlines in addition to utilizing other, more conventional financial analysis modules. Check out Collegium Pharmaceutical Backtesting and Collegium Pharmaceutical Hype Analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
Collegium |
Collegium Pharmaceutical Today Top News and Investor Outlook
Collegium Pharmaceutical Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Collegium and other traded companies coverage with news coverage. We help investors stay connected with Collegium headlines for the 26th of March to make an informed investment decision based on correlating the impacts of news items on Collegium Stock performance. Please note that trading solely based on the Collegium Pharmaceutical hype is not for everyone as timely availability and quick action are needed to avoid losses.
Collegium Pharmaceutical stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Collegium earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Collegium Pharmaceutical that are available to investors today. That information is available publicly through Collegium media outlets and privately through word of mouth or via Collegium internal channels. However, regardless of the origin, that massive amount of Collegium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Collegium Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Collegium Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Collegium Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Collegium Pharmaceutical alpha.
Collegium Largest EPS Surprises
Earnings surprises can significantly impact Collegium Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-27 | 2019-12-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2019-08-07 | 2019-06-30 | -0.17 | -0.14 | 0.03 | 17 | ||
2023-08-03 | 2023-06-30 | 0.29 | 0.34 | 0.05 | 17 | ||
2019-05-08 | 2019-03-31 | -0.24 | -0.29 | -0.05 | 20 | ||
2015-08-12 | 2015-06-30 | -0.29 | -0.34 | -0.05 | 17 | ||
2019-11-06 | 2019-09-30 | -0.12 | -0.18 | -0.06 | 50 |
Collegium Pharmaceutical Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Collegium Pharmaceutical Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
25th of March 2025
Insider Sell Scott Dreyer Sells Shares of Collegium Pharmaceutical Inc at gurufocus.com
21st of March 2025
Demoralised Delhi High Court Chief Justice On Cash Recovery From Judges Home at ndtv.com
20th of March 2025
Disposition of 1927 shares by Scott Dreyer of Collegium Pharmaceutical at 30.0005 subject ... at MacroaxisInsider
17th of March 2025
Collegium Announces Updates to its Board of Directors and Executive Leadership Team at gurufocus.com
14th of March 2025
Disposition of 2255 shares by Scott Dreyer of Collegium Pharmaceutical at 30.0049 subject ... at MacroaxisInsider
11th of March 2025
Disposition of 10445 shares by Colleen Tupper of Collegium Pharmaceutical at 30.006 subjec... at MacroaxisInsider
7th of March 2025
Collegium Pharmaceutical, Inc. EVP Shirley R. Kuhlmann Sells 26,067 Shares of Stock at thelincolnianonline.com
6th of March 2025
Collegium Recommends Calcutta High Court Judges Elevation To Top Court at ndtv.com
4th of March 2025
Collegium Pharmaceutical, Inc. Receives Consensus Recommendation of Moderate Buy from Anal... at thelincolnianonline.com
27th of February 2025
Collegium Pharmaceutical Non-GAAP EPS of 1.75 beats by 0.21, revenue of 181.9M beats at seekingalpha.com
5th of February 2025
Acquisition by Lurker Nancy of 12726 shares of Collegium Pharmaceutical subject to Rule 16... at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Collegium Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Collegium Pharmaceutical's short interest history, or implied volatility extrapolated from Collegium Pharmaceutical options trading.
Check out Collegium Pharmaceutical Backtesting and Collegium Pharmaceutical Hype Analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 1.86 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.